Novocure Ltd (NVCR)

[tw0122]

Looking good $30 +
50% 

12:09 PM EST, 12/02/2024 (MT Newswires) -- (Updates with stock move in the headline and first paragraph.)

NovoCure's (NVCR) shares rose more than 41% in recent Monday trading after the company and Zai Lab (ZLAB) said that their phase 3 trial evaluating TTFields along with gemcitabine and nab-paclitaxel as a treatment for unresectable, locally advanced pancreatic adenocarcinoma achieved its primary endpoint, demonstrating a "statistically significant" improvement in median overall survival.

NovoCure (NVCR) plans regulatory filings in the US, EU, Japan, and other major markets, while Zai Lab plans to file for regulatory approval in China, the companies said.